What the FDA approved, and for whom
In December 2024 the FDA approved tirzepatide (Zepbound) as the first medicine for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It is a weekly injection, used together with a reduced-calorie diet and more physical activity, and it acts on two gut hormone receptors, GIP and GLP-1.
The Zepbound label now lists two uses: long-term weight reduction in adults with obesity or overweight with a related condition, and OSA in adults with obesity. For sleep apnea, the label’s maintenance doses are 10 mg or 15 mg weekly, reached by stepping up over several months. Those figures are context only; your provider sets and adjusts the dose.
The approval is narrow in two useful ways. It requires obesity, and it requires OSA that is moderate or severe on a sleep study. A man with mild apnea, or apnea at a normal weight, is outside the approved use.
What the SURMOUNT-OSA trials found
The approval rests on two 52-week trials, published in the New England Journal of Medicine. Together they enrolled 469 adults, and most were men: 67% in the first trial and 72% in the second. Average BMI was about 39, and the average person had around 50 breathing interruptions an hour, well into the severe range.
The trial population also looked more like Southern California than many drug studies do. In the first trial, 20% of participants were Asian and 42% were Hispanic or Latino, according to the label’s study description.
The design answered a practical question. Trial 1 enrolled people who were not using positive airway pressure (PAP), while trial 2 enrolled people already on PAP. Everyone received diet and activity counseling.
| Result at 52 weeks | Trial 1 (no PAP) | Trial 2 (on PAP) |
|---|---|---|
| Change in events per hour, tirzepatide | minus 25.3 | minus 29.3 |
| Change in events per hour, placebo | minus 5.3 | minus 5.5 |
| At least 50% fewer events, tirzepatide vs placebo | 61.2% vs 19.0% | 72.4% vs 23.3% |
| Remission or mild OSA without daytime sleepiness | 42.2% vs 15.9% | 50.2% vs 14.3% |
Tirzepatide also lowered blood pressure, a blood marker of inflammation (hs-CRP) and the oxygen-drop burden overnight. The most common side effects were digestive, mostly mild to moderate. The trials were funded by the manufacturer.
How a weight-loss medicine changes breathing at night
OSA happens when the upper airway collapses or narrows repeatedly during sleep. The NHLBI lists obesity among the factors that narrow the airway, along with large tonsils and hormone changes. Fat stored around the neck and tongue, and in the belly, makes that collapse more likely.
Tirzepatide does not hold the airway open the way CPAP does. It works upstream, by lowering the weight that helps narrow it, which is why its effect builds over months rather than from the first night.
| CPAP | Tirzepatide | |
|---|---|---|
| How it helps | Air pressure splints the airway open | Weight loss reduces what narrows the airway |
| When it works | From the first night it is used | Gradually, as weight comes off |
| What stops the benefit | Skipping nights | Stopping the medicine, with weight regain |
| Main burdens | Mask comfort, nightly use | Stomach side effects, weekly injections, cost |
Why it sits alongside CPAP, not instead of it
The label is direct on this point: the OSA studies did not evaluate the timing or appropriateness of stopping PAP in people who were already using it well. In trial 2, PAP users paused their machines for only seven days before the key sleep test, so the results show what the medicine adds, not what happens if you give the machine up.
The numbers explain the caution. Going from about 50 interruptions an hour to about 25 is a large improvement, yet 25 an hour still sits in the moderate range on the label’s own definitions. For many men, CPAP still has work to do at that point.
The practical rule is simple. Keep using CPAP as directed, and let your sleep physician decide, ideally after a repeat sleep study, whether your settings or need for the machine have changed as you lose weight.
Why this matters for men in particular
Obstructive sleep apnea is common in men, and the NHLBI notes that untreated sleep apnea raises the risk of stroke, heart attack and other serious problems. Loud snoring, gasping during sleep and heavy daytime sleepiness are the classic clues, often reported by a partner first.
For men, sleep apnea also tangles with hormones. Poor, broken sleep is linked with lower testosterone, and excess weight drives both. Our page on sleep apnea and low testosterone explains that loop, and if you are considering testosterone therapy, read about starting TRT with sleep apnea first, because untreated apnea changes that decision.
Who should not use it, and what to watch for
Zepbound carries a boxed warning about thyroid C-cell tumors and should not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. The label also warns about severe stomach side effects, gallbladder and pancreas problems, and kidney injury from dehydration.
The label adds a warning that matters for anyone with apnea who may need surgery: aspiration has been reported during general anesthesia or deep sedation in people on GLP-1 type medicines. Our article on GLP-1s before surgery covers what to tell your anesthesia team.
People with type 2 diabetes were excluded from the OSA trials, so their results apply most directly to men without diabetes. For a side-by-side look at the two tirzepatide brands, see Mounjaro vs Zepbound.
How Ultimate Male handles sleep apnea and weight
We do not diagnose or grade sleep apnea; that belongs with a sleep study and your sleep physician. What we do is evaluate the weight side of the problem. If you have a diagnosis of moderate to severe OSA and obesity, your provider reviews your sleep study report, labs and history to see whether medical weight loss with tirzepatide fits, and how it would work alongside your existing CPAP plan.
Bring your most recent sleep study and CPAP settings to the consultation. Our shorter answer on tirzepatide for sleep apnea covers the basics, and the free 10-minute call can tell you whether an evaluation makes sense.
